

CDDF
Cancer Drug Development Forum

SPRING
CONFERENCE
2020

THE NETHERLANDS
10-12 FEBRUARY 2020

CDDF SPRING CONFERENCE 2020

NOORDWIJK AAN ZEE, NETHERLANDS

PROGRAMME

→ WWW.CDDF.ORG

EVENT OUTLINE

The Cancer Drug Development Forum (CDDF) Spring conference 2020 is a unique forum that convenes every 18 months and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives and patient advocacy groups. It is the successor of the former CDDF Alpine Conference and the 11th edition takes place from 10 to 12 February 2020, in Noordwijk aan Zee, the Netherlands.

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. The programme focuses on the latest and future challenges with a special emphasis on rational combination therapies, tumor agnostic drug development, cell therapy, and regulatory guidance on oncology drug development.

.

PROGRAMME COMMITTEE

- Jaap Verweij (CDDF Board, NL)
- Stefan Schwoch (Lilly, UK)
- Irmela Radtke (Roche, CH)
- Paul Stockman (Astrazeneca, UK)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA and national agencies), pharmaceutical industry, HTAs and patient advocates.

MEETING VENUE

Radisson Blu Hotel, Noordwijk aan Zee in NL
Pickeplein 8, 2202 CL Noordwijk aan Zee, Netherlands
+31 71 365 3000

MEETING ROOM

Jan de Raad 1-2-3 on the ground floor

MEETING SECRETARIAT

Cancer Drug Development Forum (CDDF) - info@cddf.org - www.cddf.org

c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

PROGRAMME

DAY 1 – MONDAY 10 FEBRUARY 2020

12:00	Lunch
TOPIC 1: THE RELEVANCE OF INDIVIDUAL COMPONENTS IN COMBINATION THERAPIES	
Session Chairs: Irmela Radtke (Roche, CH) & Martina Schüssler-Lenz (CAT Chair, Committee for Advanced Therapies, EMA, NL)	
13:00	**Novel Preclinical Models to Assess the Value of New Drug Combinations** James Doroshow (National Cancer Institute, US)
13:30	**Pharmacological & Clinical Trial Design Aspects** Ruth Plummer (Newcastle University, UK)
14:00	**Pharma-Industry Perspective** Stefan Schwoch (Lilly, UK)
14:30	**Regulatory Aspects and Guidances** Jorge Camarero (Spanish Agency of Medicines and Medical Devices, ES)
15:00	Coffee Break
TOPIC 2: REFLECTION ON CDDF WORKSHOPS OF LAST 18 MONTHS	
Session Chair: Jaap Verweij (CDDF)	
15:30	**Biomarkers and Patient´s Access to Personalized Oncology Drugs in Europe** Annie Pannelay (UK)
15:45	Discussion
16:00	**Minimal Residual Disease (AML/CLL)** Irmela Radtke (Roche, CH)
16:15	Discussion
16:30	**Involving Patients in Oncology Drug Development** Claudia Hey (Merck Healthcare KGaA, DE)
16:45	Discussion
17:00	**The Use of Real-World Data to Optimize Oncology Drug Development and Access** Axel Glasmacher (CDDF, DE)
17:15	Discussion
19:00	Networking Dinner (off-site)

DAY 2 – TUESDAY 11 FEBRUARY 2020

TOPIC 3: TUMOR AGNOSTIC DRUG DEVELOPMENT	
Session Chairs: Stefan Schwoch (Lilly, UK) & Herbert Kim Lyerly (Accelerating Anticancer Agent Development and Validation, US)	
09:00	**Medical Aspects** Irene Braña (Vall d'Hebron Institute of Oncology, ES)
09:35	**Pharmaceutical Industry Aspects** Todd Riehl (Genentech, US)
10:10	**Case-Study: Tumor Agnostic Approval of Larotrectinib** Chitkala Kalidas (Bayer, US)
10:40	Coffee Break
11:10	**Regulatory Aspects** TBC
11:45	Discussion (30')
12:45	Off-site Lunch (60')
TOPIC 4: CELL THERAPIES (INCL. CART-T)	
Session Chairs: Axel Glasmacher (CDDF, DE) & Giovanni Tafuri (EUnetHTA, NL)	
14:15	**Progress in Haematological Malignancies** Gerhard Ehninger (DE)
15:00	**Status in Solid Tumors** Victor Moreno Garcia (START Madrid FJD, ES)
15:45	Coffee Break
16:15	**HTA Issues** Stephen Palmer (York University, UK)
17:00	**Regulatory Aspects** Martina Schüssler-Lenz (CAT Chair, Committee for Advanced Therapies, EMA, NL)
17:45	Discussion (30')
19:00	Networking Dinner - Jan de Raad 6-7

DAY 3 – WEDNESDAY 12 FEBRUARY 2020

TOPIC 5: REGULATORY GUIDANCE ON ONCOLOGY DRUG DEVELOPMENT	
Session Chairs: Paul Stockman (Astrazeneca, UK) & Ralf Herold (European Medicines Agency, NL)	
09:00	**Update on the Revision of EMA Anti-Cancer Guideline & Regulatory Science Strategy 2025** TBC
09:45	**FDA Guidelines** Richard Pazdur (FDA, US)
10:30	Coffee Break
11:00	**Industry Aspect** Eric Rubin (Merck, US)
11:45	Panel discussion (45')
12:30	**Wrap-Up and Closure & Lunch**